Posts

Oral GLP-1 Tracker: Foundayo and Wegovy Pill Reach New Heights in Obesity Treatment Market

on

Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing

on

Merck’s Lipfendra becomes world’s first oral PCSK9 treatment approved by FDA

on

Current status: The Oral GLP-1 Tracker: Lilly takes time to build awareness for Foundayo as generic tirzepatide looms

on

BridgeBio achondroplasia pill shows compelling growth and body proportionality benefit

on

4 years after FDA snub, GSK partnership propels Spero’s Utebzi across approval finish line

on

The Oral GLP-1 Tracker: Novo’s Wegovy keeps gaining ground in obesity market

on

Oral GLP‑1 Tracker: Novo’s oral Wegovy hits 3M prescription milestone as Lilly’s Foundayo chugs along in early launch

on

KOL Insight: HR‑Positive/HER2‑Negative Breast Cancer (June 1, 2026)

on

Design Therapeutics’ Friedreich’s Ataxia Data and Vincentage’s Obesity Results from China

on

Ambrosia Biosciences Raises $100M Series B for Oral GLP-1 Drug Development

on

Merck Touts Strong Comparator Data for Enlicitide Decanoate, Oral PCSK9 Inhibitor Reducing LDL-C by Up to 60% in Phase 3 Trials

on

How GLP-1 Weight Loss Compounders Reshaped the Drug Industry

on

Novo Nordisk's Wegovy Pill Launches Strongly Amid Analyst Caution

on

Novo Nordisk Launches Wegovy Pill in the US with Broad Availability

on

Lilly seeks rapid FDA approval for oral GLP-1 orforglipron after positive obesity “switching” study

on

Kymera’s oral “Dupixent-in-a-pill” KT-621 shows strong early eczema results

on

Structure Therapeutics’ oral obesity drug shows competitive early data vs Novo and Lilly

on

Jesper Høiland Joins Alva Therapeutics' Board of Directors

on

Halda’s HLD-0915 Shows Promising First-in-Human Results as a Safer RIPTAC Cancer Therapeutic

on